Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Camptothecin is a natural pentacyclic quinoline alkaloid originally isolated from the bark of Camptotheca acuminata (the "happy tree") native to China[2][5][7]. It is a potent inhibitor of DNA topoisomerase I, an enzyme essential for DNA replication and transcription. Camptothecin binds to the topoisomerase I-DNA complex, stabilizing it and preventing re-ligation of single-strand breaks in DNA. This leads to accumulation of DNA damage and ultimately induces apoptosis in rapidly dividing cells such as cancer cells[1][2][5]. Despite strong anticancer activity observed in preclinical studies and early clinical trials—especially against breast, ovarian, colon, lung, and stomach cancers—its clinical use has been limited by poor water solubility and severe adverse effects[1][2][5][7]. These limitations have led to the development of more soluble analogues such as irinotecan and topotecan that are widely used in cancer chemotherapy today[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on camptothecin.